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Deletion of Flagellin’s Hypervariable Region Abrogates
Antibody-Mediated Neutralization and Systemic Activation
of TLR5-Dependent Immunity1
Cle´ment Nempont,* Delphine Cayet,* Martin Rumbo,† Coralie Bompard,‡ Vincent Villeret,‡
and Jean-Claude Sirard2*
TLRs trigger immunity by detecting microbe-associated molecular patterns (MAMPs). Flagellin is a unique MAMP because it harbors
1) an antigenic hypervariable region and 2) a conserved domain involved in TLR5-dependent systemic and mucosal proinflammatory
and adjuvant activities. In this study, the contribution of the flagellin domains in TLR5 activation was investigated. We showed that
TLR5 signaling can be neutralized in vivo by flagellin-specific Abs, which target the conserved domain. However, deletions of flagellin’s
hypervariable region abrogated the protein’s intrinsic ability to trigger the production of neutralizing Abs. The fact that MAMP-specific
Abs block TLR-mediated responses shows that this type of neutralization is a novel mechanism for down-regulating innate immunity.
The stimulation of mucosal innate immunity and adjuvancy to foreign Ag was not altered by the hypervariable domain deletions. In
contrast, this domain is essential to trigger systemic innate immunity, suggesting that there are distinct mechanisms for TLR5 activation
in systemic and mucosal compartments. In summary, specific MAMP determinants control the production of neutralizing Abs and the
compartmentalization of innate responses. The Journal of Immunology, 2008, 181: 2036–2043.
T oll-like receptors are instrumental in the coordinated in-duction of innate and adaptive immunity in mammals (1,2). Because TLRs are expressed by a broad variety of cell
types, they are able to trigger immunity throughout the body. Fol-
lowing infection by pathogenic microorganisms, TLRs recognize
conserved motifs referred to as microbe-associated molecular pat-
terns (MAMPs)3 (1). TLR engagement induces a gene expression
program dedicated to both innate clearance of and acquired im-
munity to pathogenic microorganisms (2). For instance, TLRs in-
duce the production of chemokines that, in turn, specifically attract
the polymorphonuclear neutrophils (PMNs) directly involved in
innate microbial clearance. Furthermore, TLRs promote the secre-
tion of pleiotropic immune mediators (such as TNF-a) and the
functional maturation of dendritic cells (DCs) that specialize in Ag
presentation to lymphocytes. Consequently, TLR agonists not only
stimulate “broadly specific” proinflammatory immune responses
but also enhance the adaptive immune response to defined Ags and
are, thus, considered to be adjuvants (3). Despite these potentially
beneficial effects, the systemic toxicity of MAMPs has prompted
efforts to develop derivatives that bias MAMP activity toward ad-
juvancy (4). Indeed, engineering molecules with unique properties
is a major challenge in manipulating immune responses.
Bacterial flagellins (the major flagella components in many bac-
terial pathogens) are specific, unique agonists for TLR5 activation
(5, 6). The FliC flagellin from Salmonella enterica serovar Typhi-
murium is the paradigm for studies on flagellum structure-func-
tion, immunity, and TLR5 signaling (6–9). It is a 494-aa protein
with two distinct domains. The amino- and carboxyl-terminal con-
served regions (comprising ;170 and 90 aa, respectively) form a
domain that is essential for TLR5 activation. Furthermore, the mo-
tif 89–96 is absolutely required (8–10). The middle (outer) do-
main of flagellin FliC comprises amino acids from positions 170–
400 and is not mandatory for TLR5 signaling (9, 10). It is
designated as a hypervariable region, since the primary sequences
greatly vary in composition and size from one bacterial species to
another. In contrast, it is known that the hypervariable region is
essential for flagellin antigenicity (11, 12). In fact, flagellins’ hy-
pervariable regions carry H-Ag specificity used for serotyping en-
teropthopathogenic bacteria, especially Salmonella strains. Dele-
tion of the central domain decreases the flagellins’ antigenicity.
For example, the S. typhimurium flagellin FliCD204–292, which is trun-
cated of 99 aa positioned in the middle part of FliC, is poorly recog-
nized by Abs directed against the whole flagellin (11). The question of
whether or not the antigenic and TLR5-activating domains can be
functionally dissociated had not been addressed until now.
TLR5 agonists are potent activators of systemic and mucosal
innate responses. We and others have shown that i.v. injection of
flagellins promotes a systemic response, characterized by the pro-
duction of proinflammatory mediators (such as TNF-a or IL-6)
and DC activation (5, 6, 13–17). Furthermore, flagellins trigger
mucosa-specific innate and adaptive defense mechanisms (18–20).
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For instance, epithelial cell lines and lung mucosa up-regulate the
production of chemokines like CXCL8 (IL-8) and CCL20 which,
in turn, recruit mucosal PMNs and DCs, respectively (18, 19).
Various authors have reported that flagellins are potent systemic
and mucosal adjuvants that elicit 1) serum and/or secretory Ab
responses and 2) Th1 and Th2 cell responses to both the flagellins
themselves and coadministered Ags (14, 17, 21, 22).
The goal of the present study was to determine whether or not
MAMP domains could alter the outcome of innate and adaptive
immune responses. Since MAMPs have adjuvant activity, they
also promote intrinsic anti-MAMP responses which, in turn, can
neutralize proinflammatory and adjuvant properties. We addressed
this issue by using flagellin as a model. We found that 1) anti-
flagellin Abs neutralize TLR5 signaling, 2) deletion of the hyper-
variable part of flagellin abrogates the latter’s ability to induce
neutralizing Abs but does not significantly alter proinflammatory
and adjuvant activities, and 3) systemic detection of flagellin does
not involve the same molecular determinants as mucosal detection.
Materials and Methods
Production of recombinant flagellins
The recombinant flagellins originated from the Salmonella enterica serovar
Typhimurium ATCC14028 flagellin FliC (accession number AAL20871).
The flagellins FliC and FliCD205–293 were either isolated from the S. typhi-
murium strains SIN22 ( fljB) and SJW46, as described previously (11, 15,
19), or purchased from Alexis Biochemicals. The constructs encoding
FliCD174–400 and FliCD191–352 were generated by PCR on a pBR322-de-
rived plasmid harboring the wild-type fliC gene under the control of its own
promoter and using the following primer pairs: AGCACCattcagcgtatcca
gacc/GCTGGTgctacaaccaccgaaaac and TCGAGatatcctgtaacagttgcagcc/
ACTCGAGgacggtacatccaaaactgcac (bases encoding a linker are in italics).
Site-directed mutagenesis was also performed on the plasmid harboring
FliCD174–400 to replace the residues 89–96 (QRVRELAV) involved in
TLR5 detection by the corresponding sequences from a nonsignaling
flagellin (DTVKVKAT); the resulting protein was thus FliCD174–400/89–96*
(8). In FliCD174–400, FliCD191–352, and FliCD174–400/89–96*, the asparagine
located six residues from the end was changed into a serine. The truncated
flagellins were purified from the supernatant of recombinant S. typhi-
murium SIN41 ( fliC fljB) as follows. Salmonella were grown in Luria-
Bertani broth for 18 h at 37°C with agitation. The supernatant was filtered
and saturated with 60% ammonium sulfate (Sigma-Aldrich). The precipi-
tated materials were recovered by centrifugation, solubilization in 20 mM
Tris-HCl (pH 7.5), and then dialysis. The proteins were further purified by
successive rounds of hydroxyapatite and anion exchange chromatography
(Bio-Rad). Lastly, the proteins were depleted of LPS using a polymyxin B
column (Pierce). Using the Limulus assay (Associates of Cape Cod), the
residual LPS concentration was determined to be ,30 pg of LPS/mg of
recombinant flagellin. When specified, flagellins were treated for 1 h at 37°
with 0.017% trypsin-EDTA (Invitrogen) to totally hydrolyze the proteins,
followed by heating at 70°C for 1 h to inactivate the trypsin. Proteins were
analyzed using standard SDS-PAGE and immunoblotting with FliC-spe-
cific polyclonal Abs.
Animal experiments
Female NMRI mice (6–8 wk old) were purchased from Charles River
Laboratories and maintained in a specific pathogen-free facility in an ac-
credited establishment (no. A59107; Institut Pasteur de Lille, Lille,
France). All experiments complied with current national and institutional
regulations and ethical guidelines. For hyperimmunization, animals were
injected s.c. with the flagellin FliC (1 mg/injection) emulsified in 200 ml of
CFA/PBS on day 1 and IFA/PBS on days 21, 35, and 49. On day 63, mice
were given 200 ml of flagellin/PBS i.v. and were sacrificed 2 h later by i.p.
injection of 5 mg of sodium pentobarbital (CEVA Sante´ Animale) for
serum and tissue sampling and analysis.
To characterize the mucosal innate response and adjuvant properties, 20
ml of PBS with or without proteins were administered intranasally (i.n.) to
mice anesthetized i.p. with 1.5 mg of ketamine (Merial) and 0.3 mg of
xylazine (Bayer) per 25-g animal. To study proinflammatory responses,
mice were sampled either at 2 h (for RNA and gene expression assays) or
6 h (to test cytokine production). For immunization assays, mice were
administered i.n. with PBS with or without LPS-depleted OVA (20 mg,
grade VII; Sigma-Aldrich) with or without flagellins (1 mg) on days 1 and
21. Bronchoalveolar lavages (BALs) and serum were sampled on day 35.
To assess neutralization, immune and mock sera were heated for 30 min at
56°C to inactivate complement. Serial serum dilutions (in 200ml of PBS) were
passively transferred to animals by the i.v. route 1 h before systemic activation
with flagellins. In some experiments, sera were mixed with flagellins diluted in
PBS and administered i.n. to test mucosal neutralization.
BALs were collected after the intratracheal injection of 1 ml of PBS
with Complete Protease Inhibitor Cocktail (Roche) and clarified by cen-
trifugation. Blood samples were collected and clotted at room temperature,
with the serum then being separated by centrifugation. Lung protein ex-
tracts were prepared by homogenizing tissue with 2 ml of T-PER Tissue
Protein Extraction Reagent (Pierce) supplemented with protease inhibitors.
All samples were stored at 280°C before analysis.
Analysis of Ag-specific Ab responses
Levels of OVA- or flagellin- specific Abs in serum and BAL samples were
assessed using ELISAs. Briefly, OVA (20 mg/well in phosphate buffer 0.2
M (pH 6.5)) and flagellin FliC (100 ng/well in PBS) were coated on Maxi-
Sorp microplates (Nalge Nunc) overnight at 4°C. All microplates were
washed with PBS/0.05% Tween 20 and then blocked with PBS/1% dry
milk for 1 h at room temperature. Serial dilutions of samples were incu-
bated for 1 h at room temperature before development. Biotinylated anti-
mouse IgG or IgA Abs (Southern Biotechnology Associates), HRP-conju-
gated streptavidin (GE Healthcare), and 3,39,5,59- tetramethylbenzidine
(BD Biosciences) were used as development reagents. The reaction was
stopped by addition of H2SO4 and the OD at 450 nm was determined. The
IgG titer was defined as the reciprocal of the highest sample dilution yield-
ing an absorbance value of 0.15 OD for OVA and 0.5 OD for FliC and was
systematically compared with a reference serum. Titers are given as geo-
metrical means of titers from individual mice. Total IgA and OVA-specific
IgA levels in BALs were measured and normalized using a calibration
curve with commercial mouse IgA (Sigma-Aldrich). The specific IgA ratio
(expressed in nanograms of OVA-specific IgA per microgram of total IgA)
was determined for each mouse.
Cytokine-specific ELISA and gene expression
Mouse CXCL2 and CCL20 and human IL-8 (CXCL8) levels were mea-
sured in serum, BALs, total lung and/or cell culture supernatant using
commercial ELISA kits (R&D Systems).
Total RNA from mouse lungs was extracted with a Nucleospin RNA II Kit
(Macherey Nagel) and reverse-transcribed with the High-Capacity cDNA Ar-
chive Kit (Applied Biosystems). The resulting cDNA was amplified using
SYBR Green-based real-time PCR (Applied Biosystems). The specific prim-
ers were CGTCATCCATGGCGAACTG/GCTTCTTTGCAGCTCCTT
CGT (ACTB, coding for b-actin), TTTTGGGATGGAATTGGACAC/
TGCAGGTGAAGCCTTCAACC (CCL20), and CCCTCAACGGA
AGAACCAAA/CACATCAGGTACGATCCAGGC (CXCL2). Relative
mRNA levels (2 2 DDCt) were determined by comparing 1) the PCR cycle
thresholds (Ct) for the gene of interest and ACTB (DCt) and 2) DCt values
for treated and control groups (DDCt) as described previously (19).
Cell-based assays
The Caco-2 human colon adenocarcinoma cell line was stably transfected with
the plasmid harboring a luciferase gene under the control of the human CCL20
promoter (23), giving rise to the Caco-Rumbo line. These intestinal epithelial
cells were grown in DMEM supplemented with 10% FCS, 10 mM HEPES,
13 nonessential amino acids, 100 U/ml penicillin, and 100 U/ml streptomycin
and (for transgene selection) 0.7 mg/ml G418 (Invitrogen). The human bron-
chial epithelial cell line BEAS-2B was cultured in Kaigh’s F12 nutrient me-
dium supplemented as for Caco-Rumbo medium plus 1 mM sodium pyruvate
and insulin-transferrin-selenium mix (Invitrogen).
Cells were stimulated with recombinant flagellins for 6 h for luciferase
assays or for 16 h before harvesting the supernatant for ELISA. Luciferase
activity in cell extracts was measured using the Bright Glo Luciferase Assay
(Promega). Relative luminescence (RLU) was normalized as a percentage of
the maximum activity with wild-type flagellin for the activation test with the
recombinant flagellins. For the in vitro neutralization test, the RLU was nor-
malized as a percentage of the maximum activity for each protein: [(RLUtreated/
RLUuntreated)/(RLUmax/RLUuntreated)] 3 100.
Statistical analysis
Statistical differences were analyzed using the Mann-Whitney U test and
were considered to be significant for p , 0.05. Unless otherwise specified,
results are expressed as arithmetic means 6 SD.
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Flagellin-specific Abs neutralize TLR5-mediated signaling
Bacterial flagellins are known to elicit strong Ab responses, which
are mainly directed against the hypervariable region (11, 12, 24).
We hypothesized that anti-flagellin Abs would neutralize the
flagellins’ TLR5-stimulating activity. Hence, mice were immu-
nized s.c. with the flagellin FliC or a mock preparation (PBS alone
or the irrelevant Ag OVA formulated in CFA), followed by boosts
with IFA. ELISA analysis revealed that the anti-FliC sera exhib-
ited specific IgG titers (.106), whereas mock sera titers were be-
low the assay’s detection threshold (102).
We and others have previously used human intestinal epithelial
cell lines as unique reporters of flagellin/TLR5 stimulatory activ-
ity, based on expression of the chemokine CCL20 (also known as
“liver-activated and -regulated chemokine,” LARC) (19, 23, 25).
Using Caco-Rumbo cells harboring the luciferase gene under the
control of the CCL20 promoter (23), we demonstrated that an anti-
FliC serum is able to fully neutralize FliC’s TLR5 agonist activity
(Fig. 1A). The neutralizing effect of FliC-specific Abs on TLR5
signaling was then directly assessed in immunized animals. To this
end, systemic proinflammatory responses in mice (production of
CCL20 and CXCL2 chemokines) were studied after i.v. injection
of FliC (Fig. 1, B and C). In mock-immunized animals, a FliC
challenge triggered a significant increase in serum levels of CCL20
and CXCL2, compared with a PBS challenge. In contrast, chemo-
kine production in FliC-immunized animals was not enhanced by
any of the challenges. Using passive serum transfer in naive ani-
mals, a close correlation was found between the amount of Ab
injected and the systemic innate response, as shown in Fig. 1D. In
conclusion, preexisting immunity to flagellin can neutralize the
latter’s TLR5-stimulating activity, both in vitro and in vivo.
Deletion of flagellin’s hypervariable region impairs antigenicity
but does not modify TLR5-stimulating activity
Since flagellin’s antigenic domain (i.e., the hypervariable central
region of the molecule) is not mandatory for TLR5 signaling, we
sought to engineer flagellin variants which could not be neutralized
by Abs (11, 24). These recombinant molecules were designed on
the basis of flagellin’s three-dimensional structure and reported
immunological properties (7–9). Two novel flagellin molecules
(FliCD191–352 and FliCD174–400, composed of 336 and 271 aa, re-
spectively) were constructed by internal deletion (Fig. 2A). As a
control, we used the previously characterized variant FliCD204–292,
which has a partial deletion in the antigenic domain (11) (Fig. 2A). As
a negative control for in vitro and in vivo experiments, mutations that
impair TLR5 signaling were introduced into FliCD174–400, yielding
the recombinant protein FliCD174–400/89–96*. The predicted structures
of the respective flagellins indicated that the motif 89–96 and the
overall structure of the conserved regions were unchanged (Fig.
2A). With the exception of FliCD204–292, the variants were unable
to complement the motility of flagellin-deficient bacteria and were
secreted into the culture supernatant.
Next, we assessed the intrinsic antigenicity of the recombinant
flagellins. To this end, saturating concentrations of flagellins were
coated onto microplates and probed by ELISA, using a hyperim-
mune serum specific for FliC or FliCD174–400. As illustrated in Fig.
2B, we observed 3- to 10-fold lower Ab titers when anti-FliC se-
rum was titrated against FliC variants than against wild-type FliC.
In contrast, the reactivity of hyperimmune serum specific for
FliCD174–400 was similar, whatever the target flagellin. These re-
sults suggest that the central hypervariable region is the major
target for anti-flagellin Abs.
Lastly, we sought to establish whether or not the recombinant
molecules retained any TLR5-stimulating activity. A dose-re-
sponse analysis was performed using Caco-Rumbo reporter cells
and the lung epithelial cell line BEAS-2B. Activation was assessed
by measuring luciferase activity in Caco-Rumbo cells and IL-8
secretion by BEAS-2B cells. As shown in Fig. 3, A and B,
FliCD204–292, FliCD191–352 and FliCD174–400 were all potent cell
activators. The flagellins’ respective EC50 values varied slightly
with the cell type but fell within the previously described nanogram
per milliliter range (9). The recombinant flagellins’ activity was found
to be fully dependent on TLR5, since FliCD174–400/89–96* was unable
to activate epithelial cells. The requirement for TLR5 signaling
was further confirmed by using bone marrow macrophages derived
from TLR5-deficient mice. The cells did not synthesize any de-
tectable IL-12 p40 (,18 pg/ml) upon stimulation with 0.5
mg/ml recombinant flagellins in contrast to cells derived from
wild-type C57BL/6 animals (ranging from 500.7 to 709.5 pg/ml
IL-12p40).
FIGURE 1. Neutralization of TLR5 signaling by flagellin-specific Abs.
NMRI mice were immunized s.c. at week 1 with 1 mg of flagellin FliC and
CFA, followed by boosts at weeks 3, 5, and 7 with FliC and IFA. In mock
conditions, animals were similarly treated with OVA and adjuvants or ad-
juvants alone. Experiments were conducted at week 9. A, In vitro TLR5-
neutralizing activity of flagellin-specific immune serum. Caco-Rumbo ep-
ithelial cells harboring the reporter construct CCL20-luc were activated for
6 h with the flagellin FliC incubated with 50% v/v FliC hyperimmune (E)
or mock (F) sera. Luciferase activity was determined and normalized to the
activity obtained with 100 ng/ml FliC. Results are representative of one of
three independent experiments. B and C, In vivo TLR5-neutralizing activ-
ity of flagellin-specific immune serum. Immunized animals (n 5 3) were
injected i.v. with PBS (f) or 0.1 mg (u) or 1 mg of flagellin FliC (M). Sera
were collected 2 h later and the concentrations of CCL20 (B) and CXCL2
(C) were determined by ELISA. D, The neutralizing activity of immune
serum. Animals (n 5 3 per dose) were passively transferred i.v. with var-
ious amounts of flagellin-specific or mock serum and treated 1 h later i.v.
with recombinant flagellins, as indicated. Chemokine production in serum
2 h postchallenge was measured by ELISA. Statistical significance (p .
0.05) was determined using the Mann-Whitney U test.
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Deleted flagellins stimulate TLR5-dependent mucosal innate
responses
TLR5 stimulation by recombinant flagellins was then studied in
vivo by the mucosal route. To this end, CCL20 and CXCL2 ex-
pression in the lungs of mice treated i.n. with flagellins was quan-
tified using quantitative RT-PCR (Fig. 3C). Within 2 h, CCL20
mRNA pulmonary levels were ;30-fold higher in animals treated
with wild-type or recombinant flagellins than in mock-treated an-
imals. Furthermore, CCL20 chemokine production was detected at
6 h after instillation, both in lung homogenates and BALs (Fig.
3D). In control experiments, FliCD174–400/89–96* and trypsin-di-
gested flagellins did not induce this type of effect. Similar findings
were observed for CXCL2 (data not shown). These results con-
firmed that the in vivo proinflammatory response was exclusively
due to the recombinant flagellins. Overall, flagellins with deletions
in the hypervariable region displayed mucosal proinflammatory
properties equivalent to those of the wild-type FliC counterpart.
Recombinant flagellins exhibit mucosal adjuvant activity
Intranasal administration of flagellins is known to promote mu-
cosal adaptive immunity (14, 22, 26). To characterize the ad-
juvant properties of our recombinant molecules, Ab responses
in serum and secretions were studied after i.n. immunizations.
OVA was used as a model Ag, formulated with or without the
various flagellins or with cholera toxin (CT) as a gold standard
mucosal adjuvant. The coadministration of FliC with OVA sig-
nificantly increased the OVA-specific IgG response (both in
serum and the BAL, ;300- and 100-fold, respectively), com-
pared with animals immunized with OVA alone (Fig. 4, A and
B). Moreover, the OVA-specific IgA response was enhanced in
BAL, thereby suggesting that FliC promotes the archetypal se-
cretory Ab response of a mucosal adjuvant (Fig. 4C). Interest-
ingly, FliC’s effect was similar to that of CT. Like FliC, the
recombinant flagellins FliCD204 –292, FliCD191–352, and
FliCD174 – 400 were thus able to potentate systemic and mucosal
responses. In contrast, FliCD174 – 400/89 –96* and trypsin-treated
flagellins lacked potency (Fig. 4 and Table I). Hence, the de-
letion of flagellin’s hypervariable region did not significantly
influence the TLR5-mediated mucosal adjuvant properties. Our
data also showed that the recombinant molecules’ respective
effects on innate and adaptive immunity are correlated.
FIGURE 2. Characteristics and cross-reactivity of hypervariable re-
gion-deleted flagellins. A, A schematic three-dimensional view of the re-
combinant flagellins. The structure of wild-type flagellin FliC is presented
in the left-hand panel using Pymol (http://www.pymol.org). In the mono-
mer, terminal regions (1–170 and 400–494) are tightly folded in a helixes
and form a structural domain involved in flagellum function. The motif
89–96 (black) is essential for TLR5 signaling. The FliC ‘‘hypervariable’’
domain is mainly constituted of b structures and b turns. Using Swiss-
Model (http://www.expasy.org/spdbv/), an overall structure was predicted
for FliCD204–292 and FliCD174–400, showing partial and total deletion of the
hypervariable region, respectively. For FliCD191–352, the positions of amino
acids delineating the deletion are shown in the left-hand panel. FliCD174–400
and FliCD191–352 contain GAAG and LELE linkers at the deletion junction,
respectively. B and C, Cross-reactivity of FliC-specific sera. Hyperimmune
sera were obtained after s.c. administration of flagellin formulated with
CFA for priming, followed by IFA boosts. Serum was titrated in ELISAs
for FliC, FliCD204–292, FliCD191–352, and FliCD174–400. The results are rep-
resentative of two experiments. B, Cross-reactivity of anti-FliC serum. C,
Cross-reactivity of anti- FliCD174–400 serum. Statistical significance (p .
0.05 in a Mann-Whitney U test) is indicated by an asterisk.
FIGURE 3. Epithelial and mucosal proinflammatory activity of hyper-
variable region-deleted flagellins. A and B, Activation of epithelial cells by
recombinant flagellins. Human epithelial cells were activated with flagel-
lins FliC, FliCD204–292, FliCD191–352, FliCD174–400, or FliCD174–400/89–96* at
the indicated concentrations. Caco-Rumbo cells harboring the reporter fu-
sion CCL20-luc were activated for 6 h and luciferase activity was normal-
ized to the maximal activity measured with saturating FliC levels (A).
BEAS-2B bronchial epithelial cells were stimulated for 16 h before mea-
suring IL-8 levels in the supernatant (B). Results are representative of one
of two independent experiments. C and D, Stimulation of the mucosal
innate response by deleted flagellins. Recombinant flagellins or trypsin-
treated preparations (1-mg equivalent) were administrated i.n. to anesthe-
tized mice (n 5 3–5). CCL20-specific mRNA levels in the whole lungs
were determined 2 h later using real-time quantitative RT-PCR (C). Six
hours after instillation, BALs (f) and lungs (M) were sampled to measure
the CCL20 concentration (D). Statistical significance (p . 0.05) was de-
termined in a Mann-Whitney U test.
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Deletion of the hypervariable region impairs the ability to elicit
anti-flagellin Abs
Deletion of the antigenic domain is expected to decrease the flagel-
lin-specific immune response and thereby any neutralization of
TLR5-mediated immunity, especially with repeated administra-
tion. We therefore decided to assess the efficacy of i.n. immuni-
zation with respect to the induction of FliC-specific Abs. As ex-
pected, FliC elicited a strong IgG response in serum and BALs
(Fig. 5). In contrast, FliCD204–292 triggered 10-fold lower Ab lev-
els in both fluids than did FliC, and a more pronounced effect was
observed after immunization with FliCD191–352 and FliCD174–400
to reach nondetectable levels as for flagellin treated with protease
(Table I). In conclusion, the flagellins’ antigenic and immunos-
timulatory domains are functionally uncoupled. Therefore,
FliCD191–352 and FliCD174–400 are molecules of interest for pre-
venting or attenuating the generation of flagellin-specific Abs with
neutralizing activity.
Removal of the hypervariable region does not impair flagellin’s
susceptibility to Ab neutralization
To determine whether or not FliCD174–400 can escape Ab-medi-
ated neutralization, we performed experiments in vitro and in vivo.
FIGURE 4. Adjuvant effect of flagellins with hypervariable region de-
letion. Mice (n5 8) were immunized i.n. with OVA with or without flagel-
lins or CT on days 1 and 21. On day 35, OVA-specific IgG titers were
measured in the serum (A) and BALs (B). The concentration of OVA-
specific IgA in BALs was determined (C). Results are representative of one
of two independent experiments. Statistical significance (p . 0.05) was
determined in a Mann-Whitney U test.
FIGURE 5. Intrinsic antigenic properties of flagellins lacking a hyper-
variable region. Mice (n 5 8) were immunized i.n. with OVA with or
without flagellins or CT or LPS on days 1 and 21. On day 35, FliC-specific
IgG titers were measured in the serum (A) and BALs (B). Results are
representative of one of two independent experiments. Statistical signifi-
cance (p . 0.05) was determined in a Mann-Whitney U test.
Table I. Protease-sensitive immune responses induced by recombinant flagellins
Intranasal Immunizationa
Anti-OVA IgGb Anti-FliC IgGb
Serum BAL Serum BAL
Mean SD Mean SD Mean SD Mean SD
PBS ND 0.0 ND 0.0 ND 0.0 ND 0.0
OVA 2.4 0.8 1.1 0.7 ND 0.0 ND 0.0
FliC 1 OVA 5.7 0.1 3.9 0.5 5.9 0.6 3.0 0.7
FliCD204–292 1 OVA 5.5 0.9 3.4 0.8 3.3 0.8 1.0 0.5
FliCD191–352 1 OVA 4.5 1.3 2.9 0.9 2.2 0.3 ND 0.0
FliCD174–400 1 OVA 4.9 0.9 2.7 0.9 2.0 0.1 0.1 0.2
TRP 1 OVA 3.4 1.2 1.3 0.8 ND 0.0 ND 0.0
FliC/TRP 1 OVA 2.8 0.5 1.1 0.6 ND 0.0 0.3 0.3
FliCD204–292/TRP 1 OVA 3.0 1.4 0.8 1.0 ND 0.0 ND 0.0
FliCD191–352/TRP 1 OVA 2.6 0.7 0.8 0.9 ND 0.0 ND 0.0
FliCD174–400/TRP 1 OVA 2.6 0.4 1.1 0.9 ND 0.0 ND 0.0
a Mice (n 5 8) were immunized i.n. with PBS, OVA, OVA plus flagellins, or OVA plus trypsin-treated flagellins (TRP) on
days 1 and 21. On day 35, OVA- and FliC- specific IgG titers were measured in the serum and BALs. Statistical significance
( p . 0.05) was determined in a Mann-Whitney test.
b Values are expressed as log 10 (reciprocal titers) 6 SD. In serum and BAL, limit of detection is 2 and 0.3 (1/100 serum
dilution and 1/2 BAL dilution), respectively. ND, Not detected.
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First, we found that an anti-FliC hyperimmune serum is able to
neutralize to a similar extent the stimulation of epithelial cells by
the TLR5 agonists FliC and FliCD174–400 (Fig. 6, A and B), indi-
cating that deletion of the hypervariable domain does not impair
neutralization. We further investigated the capacity of neutraliza-
tion in vivo. The effective doses needed to initiate TLR5-mediated
innate responses by the i.n. route was determined. FliC and
FliCD174–400 displayed similar dose-response profiles and the
0.1-mg dose was selected for subsequent neutralization assays
(Fig. 6, C and D). To this end, animals were hyperimmunized i.n.
with FliC to elicit strong, FliC-specific mucosal IgG responses
(mean titer ;45,000) and then challenged i.n. with 0.1 mg of FliC
or FliCD174–400 flagellins. Proinflammatory chemokine production
in BALs was monitored. Challenge with FliC or FliCD174–400 led
to CCL20 production (4.28 6 1.98 vs 1.08 6 0.54 ng/ml and
2.48 6 1.22 vs 0.93 6 0.48 ng/ml in mock- and FliC-immunized
mice, respectively) as observed in naive animals (Fig. 6, C and D).
Assuming that anti-FliC ELISA titers correlate to neutralizing ti-
ters (Fig. 1D), we predicted that the neutralizing activity in BALs
was too low to promote blockade of TLR5 signaling in the lungs,
whatever the type of flagellin. To definitely define whether neu-
tralization can operate in the lungs, flagellins were incubated with
anti-FliC sera before administration (Fig. 6, E and F). Both TLR5
agonistic activities of FliC and FliCD174–400 were blocked in these
conditions. In conclusion, deletion of the flagellin hypervariable
region did not enable the resulting molecules to escape from Ab
neutralization of TLR5 immune responses. These data also indi-
cated that the FliC neutralization epitopes are located within the
conserved sequences 1–173 and 401–494.
Mucosal and systemic TLR5-dependent responses depend to
different extents on the hypervariable flagellin region
We also wanted to study the neutralization by flagellin-specific
Abs of TLR5-dependent responses induced after i.v. injection of
the recombinant flagellins. To analyze the systemic activation of
innate immunity, the production in circulating proinflammatory
chemokines CCL20 and CXCL2 was measured by ELISA in se-
rum (Fig. 7). Unexpectedly, we observed that FliCD174–400 was
;100-fold impaired in its ability to trigger systemic proinflamma-
tory effects, compared with the wild-type FliC. Whereas 10 mg of
FliCD174–400 stimulated a slight chemokine production, the variant
mutated within the TLR5 motif FliCD174–400/89–96* was devoid of
activity (0.85 6 0.27 vs 0.02 6 0.00 ng/ml for CCL20). This
contrasted with FliCD204–292 and FliCD191–352, which were both
potent activators like FliC (data not shown). Hence, certain mo-
lecular determinants on the hypervariable region (or dependent on
FIGURE 6. Neutralization of TLR5 signaling induced by hypervariable
region-deleted flagellin FliCD174–400. A and B, Epithelial neutralization of
TLR5 signaling by flagellin-specific immune serum. Caco-Rumbo epithe-
lial cells harboring the reporter construct CCL20-luc were activated for 6 h
with 10 ng/ml FliC (A) or FliCD174–400 (B) incubated with various dilutions
of FliC hyperimmune (E) or mock (F) sera. Luciferase activity was de-
termined and normalized to the activity obtained with 10 ng/ml FliC or
FliCD174–400 in the absence of serum. Results are representative of one of
two independent experiments. C and D, Intranasal dose-response activity
of flagellins. Various amounts of flagellin FliC (f) or FliCD174–400 (M)
were administrated i.n. The concentrations of CCL20 (C) and CXCL2 (D)
were determined 6 h later in BALs using an ELISA. Statistical significance
(p . 0.05) was determined in a Mann-Whitney U test. E and F, In vivo
neutralization of TLR5 activity stimulated by FliCD174 – 400. Animals
(n 5 3 per dose) were instilled i.n. with 50 ng of FliC (E) or FliCD174–400
(F) supplemented with various quantities of anti-FliC or mock sera as
indicated. Chemokine production in BAL was assessed by ELISA 6 h
postchallenge. Statistical significance (p . 0.05) was determined in a
Mann-Whitney U test.
FIGURE 7. Alteration of the systemic activation ability of hypervari-
able region-deleted flagellin FliCD174–400. Various amounts of flagellin
FliC (f) or FliCD174–400 (M) were administrated i.v. The concentrations of
CCL20 (A) and CXCL2 (B) were determined 2 h later in the serum using
an ELISA. Statistical significance (p . 0.05) was determined in a Mann-
Whitney U test.
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the latter) are required for systemic TLR5 stimulation but not mu-
cosal TLR5 stimulation. Taken as a whole, our results indicate that
TLR5 activation within the mucosal and the systemic compart-
ments is controlled by distinct mechanisms.
Discussion
Over recent years, flagellins have been the focus of many studies on
the role of TLR5 in systemic and mucosal immunity (6). In addition
to TLR5-dependent stimulatory activity, flagellins display strong an-
tigenic potency. Thus, flagellins are immunodominant Ags in the
body’s responses to pathogenic bacteria and in chronic inflammatory
disorders, since they elicit prominent T cell and Ab responses (6,
27–29). This dual nature as an innate immunity activator and an Ag
means that flagellins are attractive immunological models. It is known
that flagellins are constituted by a conserved domain (with a TLR5-
activating motif) and a hypervariable region (assigned to antigenicity,
especially Ab response) (9, 11, 12). In this study, we sought to es-
tablish whether TLR5 signaling can be regulated by flagellin-specific
Abs and whether TLR5-stimulating and antigenic activities are linked
and affect each other. Using truncated forms of the S. typhimurium
flagellin FliC and anti-FliC hyperimmune serum, we showed for the
first time that preexisting flagellin-specific Abs are capable of neu-
tralizing TLR5 signaling effects in vivo. Additionally, we demon-
strated that deletion of flagellin’s hypervariable region promotes es-
cape from neutralization by decreasing the protein’s potency for
generating antagonistic Abs. These data support that the flagellin
TLR5-stimulating and antigenic domains can be dissociated but that
their respective activities can affect the final outcome of immune re-
sponses. Lastly, we found that TLR5 signaling is compartmentalized,
since the FliCD174–400 flagellin (i.e., lacking the hypervariable region)
stimulated immunity in the mucosa but was devoid of any systemic
activity.
Whereas innate TLR signaling clearly orchestrates adaptive im-
munity, the reverse process has been little explored. Although re-
cent evidence supports an Ag-independent role for T lymphocytes
in the regulation of innate immunity (30), the question of how B
cells and, in particular, TLR agonist-specific Abs influence innate
responses has not been resolved. Our study indicates that animals
can develop flagellin-specific Abs that efficiently neutralize the
onset of TLR5-mediated responses in vitro and in vivo (Figs. 1 and
7). Therefore, in vivo blockade of TLR signaling by MAMP-spe-
cific neutralization Abs is a novel mechanism for down-regulating
innate immunity. Our results are consistent with the report by Saha
et al. (31), which suggested that ex vivo Ab blockade of the TLR5
activation motif of Pseudomonas aeruginosa flagellin reduces its
efficacy to induce lung innate responses. Interestingly, we found
that neutralizing epitopes in S. typhimurium FliC are embedded
within the conserved region (regions 1–173 and 401–494) that also
carries the activation motif 89–96 (8, 9). We did not perform any
cross-neutralization experiments using flagellins isolated from
other bacteria: however, if neutralizing Abs indeed target the con-
served TLR5 signaling motif with high affinity, one can expect
blockade of the innate responses to any flagellins. We further dem-
onstrated that the mechanisms of action of flagellin-specific Abs
rely on immediate neutralization of TLR5 signaling, since NF-kB-
dependent chemokine gene transcription was not turned on early
after challenge (Fig. 3). It is known that LPS can be sequestered by
secretory IgA within endosomes in intestinal epithelial cells,
thereby blocking TLR4-mediated NF-kB activation (32). Hence,
one can assume that high-affinity flagellin-specific neutralizing
Abs bind to the flagellin signaling motif and thereby prevent any
interaction between flagellin and its cognate detector TLR5. Fur-
ther investigations with flagellin-specific mAbs are needed to dis-
sect the mode of action and the Abs targets.
TLR signaling neutralization is a major strategy for managing
uncontrolled inflammation in sepsis or chronic disease (33). Dif-
ferent targets can promote a TLR signaling blockade, including
TLRs themselves and cognate MAMPs. Most efforts seek to block
the TLRs and a recent study showed that an anti-TLR4 mAb ef-
ficiently inhibited LPS-induced immune responses in acute
polymicrobial infections (34). As shown in the present work,
MAMP targeting represents an effective and attractive neutraliza-
tion strategy. Chronic TLR stimulation may contribute to the phys-
iopathology of some diseases and, when conjugated with the in-
trinsic adjuvant and antigenic activities of MAMPs, it may elicit
anti-MAMP-neutralizing Abs. In turn, the neutralization of TLR-
specific responses could fully suppress innate responses. Flagel-
lin’s hypervariable region is not essential for signaling (Figs. 3 and
4), a finding which is consistent with the known TLR5 stimulatory
activity of Listeria monocytogenes flagellin, which almost com-
pletely lacks a variable region (5). Thus, flagellated bacteria could
evade host defenses by facilitating the production of Abs that re-
duce the host’s ability to mount an innate immune response. The
high antigenicity of the flagellin variable domain may be critical in
the potentiation of this type of Ab production. Remarkably, the
study by Honko et al. (22) showed that i.n. administered anti-
flagellin Abs were unable to interfere with TLR5. Accordingly, we
were unable to detect neutralization in similar conditions.
In contrast to profilin (that depends on TLR11 for effective antige-
nicity (35)), flagellin’s reduced immunogenicity following hypervari-
able region deletion does not rely on a TLR5 signaling failure. The
deletion of major Th or B epitopes may explain the decreased ability
of FliCD174–400 to elicit Abs. Previous studies identified a dominant
Th epitope in flagellin’s conserved domain and highlighted a major
role for CD4 T cells in Ab responses (29, 36). Deletion of flagellin’s
hypervariable region is therefore not absolutely required for effective
help for B cell responses. Likewise, i.n. coadministration of
FliCD174–400 with OVA (which provides external help) did not
enhance anti-FliC Ab titers, compared with instillation of
FliCD174–400 alone. It seems that deletion of a dominant B cell
epitope on the hypervariable region is essential for presentation of
a subdominant, neutralizing epitope located within the conserved
region.
We previously suggested that early epithelial CCL20 production
correlates with mucosal adjuvant properties, probably through DC
recruitment within the mucosa (19). Our study supports this paradigm,
since the mucosal adjuvancy of flagellin molecules correlates with
early CCL20 production in lung tissue and BALs (Figs. 3, 6, and 7).
TLR5 signaling is absolutely required for flagellin-induced enhance-
ment of immune responses to coinstilled Ags. The deleted flagellin
FliCD174–400 also retains adjuvant properties when administered s.c,
suggesting that mucosal and dermal responses behave similarly and
thus differ from the systemic response (data not shown). Studies with
the S. typhimurium flagellin FljB (which harbors a similar deletion in
the hypervariable region) have been recently performed with a view to
using this type of molecule as an Ag carrier (14, 21). Similar findings
were obtained using the deleted flagellin FljB as a carrier for foreign
Ags in s.c. immunization (21).
The use of wild-type flagellin as an adjuvant could lead to harmful
effects because production of neutralizing Abs may attenuate both the
booster effect of the adjuvant and the innate responses to pathogenic
flagellated bacteria. We established that FliCD174–400 has more prom-
inent beneficial properties, due to its poor capacity to generate neu-
tralizing Abs. In addition, we found that FliCD174–400 is strongly at-
tenuated for systemic signaling compared with wild-type flagellin,
whereas mucosal activity was unaffected. This type of effect has been
already observed for the TLR4 agonist LPS (4). Recent observations
indicated that LPS’s molecular features are essential for its biological
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activity (4, 37, 38). The LPS’s O chain composition, the number and
the length of the acyl chains, and the type of substitutions all affect the
outcome of TLR4 signaling. Discrimination relies on a specific com-
bination of coreceptors and adaptor molecules. Indeed, the monophos-
phoryl lipid A is a portion of LPS that preferentially signals through
the adaptor Toll/IL-1R domain-containing adapter inducing IFN-b
(TRIF) but not MyD88, thereby rendering the molecule less toxic but
nevertheless adjuvant (4). Moreover, signaling in the mucosa only has
indeed been observed for LPS. For instance, bladder epithelial cells
are devoid of the LPS coreceptor CD14 but can detect uropathogenic
Escherichia coli LPS by using alternative mechanisms involving fim-
briae (38). Interestingly, asialo-GM1 has been proposed as a flagellin
coreceptor in the lung (39). Lastly, it has been shown that intracellular
detectors like IL-1-converting enzyme protease-activating factor
(IPAF) and neuronal apoptosis inhibitory protein 5 (NAIP5) partici-
pate in flagellin detection (40). Whether flagellin-mediated activation
operates according to the same mechanisms in both mucosal and sys-
temic compartments remains to be determined.
Our findings open up new prospects for the development of
antagonistic strategies for manipulating host innate responses and
specific inflammatory disorders. Further studies will have to es-
tablish whether or not the neutralization of various MAMPs pro-
tects or exacerbates bacterial infections or inflammatory diseases.
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